Wellgistics Health (WGRX) Stock Price, News & Analysis

Company Overview

Wellgistics Health (NASDAQ: WGRX) is a Tampa, Florida-based digital health company that integrates telemedicine, diagnostic testing and last-mile logistics into a unified platform. Through its proprietary technology, the company connects patients, healthcare providers and laboratories, enabling real-time virtual consultations alongside at-home specimen collection and direct delivery of prescription medications and supplies. By streamlining clinical workflows and automating logistics, Wellgistics Health aims to improve patient access to care while reducing administrative burden for medical practices.

Founded in 2018 by a team of healthcare and technology veterans, Wellgistics Health launched its telehealth service line in early 2019 and added in-home diagnostic capabilities later that year. In 2021, the company completed a business combination with a special purpose acquisition company (SPAC) and began trading on the Nasdaq under the ticker WGRX. In mid-2023, it rebranded as Wellgistics Health to reflect its expanded focus on end-to-end care delivery and supply-chain solutions within the broader health ecosystem.

Wellgistics Health currently serves patients across more than 30 U.S. states through partnerships with regional health systems, insurers and employer groups. Its offerings include chronic disease management programs, pre-procedure screening services and COVID-19 testing logistics, all supported by an on-demand network of certified phlebotomists and courier partners. The company is also exploring strategic alliances in Canada and Western Europe to extend its digital health and logistics framework internationally.

The company’s leadership team combines clinical, operational and technology expertise. Chief Executive Officer Jessica Taylor previously led product development at a leading telehealth organization, while Chief Operating Officer Sarah Lee brings over a decade of experience in medical supply-chain management. Together with Chief Financial Officer Mark Reynolds, Wellgistics Health’s executive team is focused on scaling its platform, enhancing clinical outcomes and driving partner adoption in an increasingly virtualized care environment.

Key Stats

• Today's Range: $0.82 to $0.95
• 50-Day Range: N/A
• 52-Week Range: $0.82 to $7.04
• Volume: 190,114 shs
• Average Volume: 314,759 shs
• Market Capitalization: $61.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

WGRX Stock Analysis - Frequently Asked Questions

How have WGRX shares performed this year?

Wellgistics Health's stock was trading at $1.33 at the beginning of the year. Since then, WGRX stock has decreased by 33.1% and is now trading at $0.89.

When did Wellgistics Health IPO?

Wellgistics Health (WGRX) raised $4 million in an IPO on Friday, February 21st 2025. The company issued 900,000 shares at $4.50-$5.50 per share. Craft Capital and D. Boral Capital (ex-EF Hutton) served as the underwriters for the IPO.

When does the company's lock-up period expire?

Wellgistics Health's lock-up period expires on Wednesday, August 20th. Wellgistics Health had issued 888,889 shares in its public offering on February 21st. The total size of the offering was $4,000,001 based on an initial share price of $4.50. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

How do I buy shares of Wellgistics Health?

Shares of WGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Wholesale
• Current Symbol: NASDAQ:WGRX
• CIK: 2030763
• Web: N/A
• Phone: 1-843-302-1785
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.43
• Current Ratio: 0.36
• Quick Ratio: 0.15

Sales & Book Value

• Annual Sales: $18.13 million
• Price / Sales: 3.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 71,860,000
• Free Float: N/A
• Market Cap: $61.80 million
• Optionable: N/A
• Beta: N/A